RECOVERY FOOTWEAR LEADER OOFOS LAUNCHES THE OOmy ZEN, A SHOE THAT TRANSCENDS COMFORT
The OOmy Zen is a minimalist masterpiece for everyday wear
The OOmy Zen offers effortless wearability for everyday moments and movements through a harmonious blend of seamless knit and OOfoam™ technology. Designed with simplicity at the forefront, the OOmy Zen features a precisely engineered seamless circular knit upper with bands that mimic the peaceful lines of a zen garden and hug the heel and instep. The seamless upper was developed to reduce pressure for a secure, sock-like fit that offers ultimate pliability, flexibility and mobility in a lightweight package. A new, advanced version of OOFOS' patented footbed features a rounded, cupped heel design to enhance impact absorption and stability with every step. This evolved footbed couples with the brand's proprietary OOfoam™ technology to absorb impact like no other. The result is less constriction and more freedom; less pressure, more relief – a shoe that is made to move the way your body moves.
The OOmy Zen design team, led by footwear industry veteran,
The restorative journey begins on
About OOFOS
OOFOS is the global leader in recovery footwear, founded by a team of industry veterans looking to help runners and fitness enthusiasts recover better from their workouts. Made with revolutionary OOfoam™ technology, OOFOS are designed to absorb 37% more impact than traditional footwear. They reduce stress on joints to keep anyone, of any activity level, feeling their best. From professional athletes to casual walkers, OOFOS footwear will make your hard-working feet and body feel better – all you have to do is feel the OO. For more information, go to www.oofos.com.
Contact:
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/recovery-footwear-leader-oofos-launches-the-oomy-zen-a-shoe-that-transcends-comfort-302371315.html
SOURCE OOFOS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development
- Shanghai Electric Secures First Overseas Heavy-Duty Gas Turbine Order for 500 MW Malaysian Project
- Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share